Igene Biotechnology, Inc.
IGNE
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -99.65% | -35.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -99.65% | -35.67% |
| Cost of Revenue | -- | -- | -- | -102.30% | -62.55% |
| Gross Profit | -- | -- | -- | 122.33% | 30.34% |
| SG&A Expenses | -45.56% | -10.37% | -42.74% | -47.83% | -24.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 7.38% | -50.44% | -17.12% | -- | -- |
| Total Operating Expenses | -82.47% | -93.21% | -88.88% | -91.08% | -72.51% |
| Operating Income | -116.69% | 53.09% | -72.03% | 81.33% | 332.93% |
| Income Before Tax | -646.34% | -34.77% | -178.79% | 71.73% | 114.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -646.34% | -34.77% | -178.79% | 71.73% | 114.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -646.34% | -34.77% | -178.79% | 71.73% | 114.38% |
| EBIT | -116.69% | 53.09% | -72.03% | 81.33% | 332.93% |
| EBITDA | -108.08% | 63.15% | -183.10% | 81.68% | 456.14% |
| EPS Basic | -500.00% | -25.00% | -180.00% | 93.94% | 101.39% |
| Normalized Basic EPS | -- | -50.00% | -100.00% | 90.00% | 100.00% |
| EPS Diluted | -500.00% | -25.00% | -180.00% | 93.94% | 101.39% |
| Normalized Diluted EPS | -- | -50.00% | -100.00% | 90.00% | 100.00% |
| Average Basic Shares Outstanding | 0.76% | 3.09% | 2.91% | 274.02% | 1,308.02% |
| Average Diluted Shares Outstanding | 0.76% | 3.09% | 2.91% | 274.02% | 1,308.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |